These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24590932)

  • 21. Economic and epidemiological impact of early antiretroviral therapy initiation in India.
    Maddali MV; Dowdy DW; Gupta A; Shah M
    J Int AIDS Soc; 2015; 18(1):20217. PubMed ID: 26434780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.
    Vijayaraghavan A; Efrusy MB; Mazonson PD; Ebrahim O; Sanne IM; Santas CC
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):91-100. PubMed ID: 17621241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy.
    McManus H; O'Connor CC; Boyd M; Broom J; Russell D; Watson K; Roth N; Read PJ; Petoumenos K; Law MG;
    PLoS One; 2012; 7(11):e48839. PubMed ID: 23144991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.
    Severe P; Juste MA; Ambroise A; Eliacin L; Marchand C; Apollon S; Edwards A; Bang H; Nicotera J; Godfrey C; Gulick RM; Johnson WD; Pape JW; Fitzgerald DW
    N Engl J Med; 2010 Jul; 363(3):257-65. PubMed ID: 20647201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
    del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
    Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.
    Le T; Wright EJ; Smith DM; He W; Catano G; Okulicz JF; Young JA; Clark RA; Richman DD; Little SJ; Ahuja SK
    N Engl J Med; 2013 Jan; 368(3):218-30. PubMed ID: 23323898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinician practices and attitudes regarding early antiretroviral therapy in the United States.
    Kurth AE; Mayer K; Beauchamp G; McKinstry L; Farrior J; Buchacz K; Donnell D; Branson B; El-Sadr W;
    J Acquir Immune Defic Syndr; 2012 Dec; 61(5):e65-9. PubMed ID: 23183150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.
    Hoffmann CJ; Schomaker M; Fox MP; Mutevedzi P; Giddy J; Prozesky H; Wood R; Garone DB; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):34-41. PubMed ID: 23344547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.
    Siegfried N; Davies MA; Penazzato M; Muhe LM; Egger M
    Cochrane Database Syst Rev; 2013 Oct; 10(10):CD010309. PubMed ID: 24114324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
    Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
    AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integration of antiretroviral therapy with tuberculosis treatment.
    Abdool Karim SS; Naidoo K; Grobler A; Padayatchi N; Baxter C; Gray AL; Gengiah T; Gengiah S; Naidoo A; Jithoo N; Nair G; El-Sadr WM; Friedland G; Abdool Karim Q
    N Engl J Med; 2011 Oct; 365(16):1492-501. PubMed ID: 22010915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.
    Long EF; Brandeau ML; Owens DK
    Ann Intern Med; 2010 Dec; 153(12):778-89. PubMed ID: 21173412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.
    Ishikawa N; Shimbo T; Miyano S; Sikazwe I; Mwango A; Ghidinelli MN; Syakantu G
    PLoS One; 2014; 9(3):e90991. PubMed ID: 24604067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.
    Sax PE; Sloan CE; Schackman BR; Grant PM; Rong J; Zolopa AR; Powderly W; Losina E; Freedberg KA;
    HIV Clin Trials; 2010; 11(5):248-59. PubMed ID: 21126955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.